证券代码：002793 证券简称：罗欣药业 公告编号：2025-097 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第六次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司 规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规 定。 4、会议时间： （1）现场会议时间：2025年11月14日14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：本次股东会采取现场投票与网络投票相结合的方式。 罗欣药业集团股份有限公司 关于召开2025年第六次临时股东会的通知 公司将通过深圳证券交易所交易系统和互 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-096 罗欣药业集团股份有限公司 第五届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 10 月 27 日，罗欣药业集团股份有限公司（以下简称"公司"）第 五届董事会第三十二次会议在山东省临沂高新技术产业开发区罗七路管理中心 三楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结 合的方式召开。会议通知已于 2025 年 10 月 24 日以电话、专人送达、电子邮件 等方式发出。本次会议应出席董事 6 名，实际出席董事 6 名，公司高级管理人员 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》（以下简称"《公司法》"）等法律法规、规范性文件和 《罗欣药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，合 法有效。 二、董事会会议审议情况 （一）审议通过《关于 2025 年第三季度报告的议案》 董事会编制和审议公司 2025 年第三季度报告的程序符合法律法规和中国 ...

罗欣药业集团股份有限公司 2025 年第三季度报告 证券代码：002793 证券简称：罗欣药业 公告编号：2025-098 罗欣药业集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 646,173,009.72 | 3.94% | 1,723,415,167.25 | -8.37% | | 归属于上市公司股东 | 5,231,766.19 | 102.96% | 22,926,815.63 | ...

Core Insights - The company reported third-quarter revenue of 646 million yuan, representing a year-on-year increase of 3.94% [1] - Net profit for the third quarter was 5.23 million yuan, showing a significant year-on-year growth of 102.96% [1] - For the first three quarters, the company achieved revenue of 1.723 billion yuan, which is a year-on-year decline of 8.37% [1] - The net profit for the first three quarters was 22.93 million yuan, reflecting a year-on-year increase of 108.64% [1]

目 录 | 一、前次募集资金使用情况鉴证报告………………………………第 | | 1—2 | 页 | | --- | --- | --- | --- | | 二、前次募集资金使用情况报告………………………………… | 第 | 3—12 | 页 | | 三、附件………………………………………………………… | 第 | 13—16 | 页 | | （一）本所营业执照复印件…………………………………… | | 第 13 | 页 | | （二）本所执业证书复印件…………………………………… | | 第 14 | 页 | | （三）签字注册会计师执业证书复印件………………… | 第 | 15—16 | 页 | 前次募集资金使用情况鉴证报告 天健审〔2025〕6-539 号 罗欣药业集团股份有限公司全体股东： 我们鉴证了后附的罗欣药业集团股份有限公司（以下简称罗欣药业公司）管 理层编制的截至 2024 年 12 月 31 日的《前次募集资金使用情况报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供罗欣药业公司向特定对象发行股票时使用，不得用作任何其 他目的。我们同意本鉴证报告作为罗欣药业公司向特定对象发行股票的必备 ...

的鉴证报告 目 录 一、最近三年及一期非经常性损益的鉴证报告……………………第 1—2 页 二、最近三年及一期非经常性损益明细表…………………………第 3—4 页 关于罗欣药业集团股份有限公司 最近三年及一期非经常性损益 三、最近三年及一期非经常性损益明细表附注………………… 第 5—6 页 | 四、附件……………………………………………………………第 7—10 | | 页 | | --- | --- | --- | | （一）本所营业执照复印件……………………………………………第 | 7 | 页 | | （二）本所执业证书复印件……………………………………………第 | 8 | 页 | | （三）签字注册会计师执业证书复印件…………………………第 9—10 | | 页 | 关于罗欣药业集团股份有限公司 最近三年及一期非经常性损益的鉴证报告 天健审〔2025〕6-538 号 罗欣药业集团股份有限公司全体股东： 我们审核了后附的罗欣药业集团股份有限公司（以下简称罗欣药业公司）管 理层编制的最近三年及一期非经常性损益明细表（2022－2024 年度以及 2025 年 1－9 月）及其附注（以下简称非经常性损益明细表 ...

Core Viewpoint - 罗欣药业's stock has experienced fluctuations, with a year-to-date increase of 40.84%, but a recent decline of 4.27% over the last five trading days, indicating volatility in investor sentiment and market performance [1][2]. Company Overview - 罗欣药业, established on May 11, 1998, and listed on April 15, 2016, is located in Linyi City, Shandong Province, and focuses on the research, production, and sales of pharmaceutical products [1]. - The company's revenue composition includes 49.54% from digestive system products, 22.12% from antibiotics, 11.74% from other categories, 10.10% from agency products, 4.71% from respiratory system products, and 1.79% from other supplements [1]. Financial Performance - For the first half of 2025, 罗欣药业 reported a revenue of 1.077 billion yuan, a year-on-year decrease of 14.45%, while the net profit attributable to shareholders was 17.695 million yuan, showing a significant increase of 119.95% [2]. - The company has distributed a total of 330 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of October 20, 2023, 罗欣药业 had 48,300 shareholders, an increase of 26.23% from the previous period, with an average of 22,481 circulating shares per shareholder, a decrease of 20.78% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 15.2242 million shares as a new shareholder [3]. Market Activity - The stock price of 罗欣药业 was reported at 5.38 yuan per share, with a trading volume of 68.3054 million yuan and a turnover rate of 1.16% [1]. - The stock has appeared on the龙虎榜 twice this year, with the most recent appearance on July 31 [1].

Core Viewpoint - Luo Xin Pharmaceutical (002793) is experiencing fluctuations in stock performance and investor sentiment, with recent developments indicating a mixed outlook for the company and the pharmaceutical industry as a whole. Group 1: Stock Performance - As of October 21, 2025, Luo Xin Pharmaceutical's stock closed at 5.47 yuan, down 0.18%, with a turnover rate of 3.84% and a trading volume of 416,500 shares, amounting to a transaction value of 227 million yuan [1]. - On October 21, 2025, the net outflow of funds from major investors was 21.91 million yuan, while retail investors saw a net inflow of 25.77 million yuan [4]. Group 2: Shareholder Information - The total number of shareholders as of October 20, 2025, was 48,304, with 30,338,341 shares held by deep stock connect investors as of September 30, 2025 [2][3]. - The total number of shareholders as of September 30, 2025, was 38,267 [3]. Group 3: Company Operations and Financials - The company reported significant improvement in performance driven by the innovative drug Tegoprazan, with net profit turning positive in the first half of 2025 [3]. - The company maintains a complete industrial chain from raw materials to formulations, producing over 150 varieties of products across various forms, including tablets and injections [3]. - The company emphasizes that its operations are ongoing and that there has been no disruption in business activities despite market challenges [3].

Core Insights - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical has attracted significant attention in the capital market, highlighting a trend of top financial talents transitioning into core management roles in the real economy [2][4] - Jiang Ying's background as a fund manager at Guotai Fund, along with her impressive academic credentials, reflects a growing trend of financial professionals moving into corporate governance positions [4][5] - The shift of fund managers to roles such as Secretary of the Board indicates a deeper integration of finance and the real economy in China, as well as a response to the evolving demands of the asset management industry [8][10] Company Insights - Jiang Ying, born in October 1987, has a strong educational background with dual degrees in Science and Economics from Peking University, a Master's in Management from Peking University, and a Master's in Finance from the University of Hong Kong [4] - During her tenure at Guotai Fund, Jiang managed three funds with a total management time exceeding four years, but her performance was subpar, with negative returns across all funds managed [4][5] - The management scale of the funds she oversaw peaked at 2.59 billion yuan in Q1 2022 but dropped to 643 million yuan by December 2024 [4] Industry Trends - The trend of fund managers transitioning to Secretary of the Board roles is indicative of a broader shift in the asset management industry, moving from a focus on scale expansion to quality improvement [8][9] - The competitive landscape in the asset management sector has intensified, leading to a significant number of fund managers reassessing their career paths, with 333 fund managers leaving their positions in 2023 alone [9][10] - The increasing demand from listed companies for talents with financial insights and resource integration capabilities is driving fund managers to explore opportunities in corporate management and entrepreneurship [9][10] Talent Movement - The movement of fund managers into various roles, including Secretary of the Board, reflects a new trend in talent mobility within the financial sector, reshaping corporate governance and enhancing the connection between finance and the real economy [11][12] - This trend is seen as a response to the need for high-quality development in China's economy, with financial professionals bringing industry research and resource integration skills to help enterprises connect with capital markets [11][12] - The shift also indicates a growing recognition of the importance of financial talent in enhancing corporate governance and investor relations, ultimately benefiting the overall market structure [11][12]

Core Insights - The private hospital sector saw a slight increase of 0.29%, ranking 9th among concept sectors, with 32 stocks rising, including Guizhou Bailing and Luoxin Pharmaceutical hitting the daily limit [1][2] Sector Performance - The top-performing concept sectors included Hainan Free Trade Zone (+2.58%) and Military Equipment Restructuring (+1.98%), while sectors like Special Steel (-2.68%) and Photolithography (-2.47%) faced declines [2] - The private hospital sector attracted a net inflow of 201 million yuan, with 29 stocks receiving inflows, and 6 stocks exceeding 50 million yuan in net inflow [2] Stock Highlights - Notable stocks in the private hospital sector included: - New Mileage: +9.87% with a net inflow of 161.24 million yuan and a net inflow ratio of 19.36% [3] - Guizhou Bailing: +9.98% with a net inflow of 95.37 million yuan and a net inflow ratio of 33.91% [3] - Luoxin Pharmaceutical: +9.94% with a net inflow of 77.86 million yuan and a net inflow ratio of 35.07% [3] - Other significant gainers included Hainan Haiyao (+6.14%) and Xinfeng Pharmaceutical (+3.20%) [1][3] Decliners - The stocks with the largest declines included: - Pingtan Development: -4.53% [1] - Xiangjiang Holdings: -3.06% [7] - Anke Biotechnology: -2.48% [7]